InvestorNewsBreaks – Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology
Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. “Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (‘SABCS’), highlighting that its Deciparticle(TM) platform can package even the toughest, water-resistant drugs into smaller, uniform nanoparticles that are small…